BriaCell Therapeutics Corp. Email Format

Biotechnology ResearchPennsylvania, United States11-50 Employees

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing immunotherapies to transform cancer care. It is based in Philadelphia, Pennsylvania, and operates within the biotechnology research sector. The company trades on Nasdaq and the TSX, reflecting its international share listings. 

Its pipeline includes Bria-OVA+, aimed at ovarian cancer, described as a next-generation, off-the-shelf, cell-based immunotherapy; it also pursues Bria-OTS+ for breast cancer as part of its personalized immunotherapy program. In pursuit of these programs, BriaCell has established collaborations, including a partnership with MSK Accelerator to advance Bria-OTS+ for breast cancer. The company has presented clinical and preclinical data at major oncology meetings, such as the AACR Annual Meeting in 2026.

Sign up for free to view info

Company overview Employee directory